HK Stock Market Move | LAEKNA-B(02105) rose by over 8%, the self-developed new drug LAE120 has received approval for clinical trials from the US FDA.

LAEKNA-B (02105) surged more than 8%, rising by 8.63% to HK$13.6 as of press time, with a turnover of HK$83.7023 million. On the news front, Laike Pharmaceutical announced this morning that the Food and Drug Administration (FDA) in the United States has approved its self-developed drug LAE120, a new drug clinical trial application (IND) for a potent and highly selective USP1 inhibitor for the treatment of late-stage solid tumor patients. The company stated that it is actively pursuing external collaborations to accelerate the clinical development progress of LAE120. In addition to LAE120, another self-developed potential anti-tumor drug, LAE118 (PI3K mutation selective inhibitor), has also entered the IND supporting research (IND-enabling) stage. Dr. Lv Xiangyang, CEO of Laike Pharmaceutical, stated that the approval of another early-stage development project for IND demonstrates the company's strength in the field of new drug research and development. The company will continue to focus on the three major areas of obesity, cancer, and liver fibrosis, and advance and enrich its product pipeline. In November 2024, the group reached a clinical cooperation agreement with Lilly to jointly accelerate the global clinical development of LAE102 for the treatment of obesity. In the future, the company plans to establish strategic partnerships with leading pharmaceutical companies worldwide to accelerate the clinical development and commercialization process of candidate drugs, providing revolutionary therapy for global patients.